Share Name Share Symbol Market Type Share ISIN Share Description
Syncona LSE:SYNC London Ordinary Share GG00B8P59C08 ORD NPV
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.50p +0.22% 223.50p 224.00p 225.00p 225.00p 224.00p 225.00p 269,053 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 28.7 5.1 0.8 286.5 1,474.99

Syncona Share Discussion Threads

Showing 18326 to 18350 of 18350 messages
Chat Pages: 734  733  732  731  730  729  728  727  726  725  724  723  Older
DateSubjectAuthorDiscuss
19/6/2018
08:26
Plenty going on here. Two new investments plus today’s increased investment in Freeline. And a strategic theme in gene therapy.
brexitplus
15/6/2018
03:37
The results presentation: htTps://www.synconaltd.com/wp-content/uploads/2017/07/Syncona-Full-Year-Results-Presentation-14062018.pdf And the results themselves: httPs://www.synconaltd.com/wp-content/uploads/2017/07/Syncona-Ltd-Full-Year-Results-2018.pdf
rambutan2
14/6/2018
12:06
Indeed all is looking good and whilst its a little out of the limelight the price remains a bargain in my opinion. I added today and plan to add more should there be any dips.
audigger
14/6/2018
11:11
Nitestar awarded Rmat which is the road to “accelerated approval”
ltinvestor
14/6/2018
07:36
Totally agree. The approach and choice of investments is excellent. Very professional.
brexitplus
14/6/2018
07:24
I am quite amazed by the lack of Pi interest in Syncona.Todays results give a snapshot of the potential here with regard to their investments in the field of gene therapy....
ltinvestor
13/6/2018
08:01
Autolus to ipo on Nasdaq 22/6
ltinvestor
10/6/2018
12:59
Autolus has a unique advantage over other car T therapies in that their car T has a built in “off switch”.This will help reduce adverse reactions found with other T cell therapies.Autolus excites me more than their other subsidiary holdings and in time has the potential to be worth billions...
ltinvestor
08/6/2018
12:25
Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶1;) has filed an amended registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering in the United States of its American Depositary Shares (“ADSs”), each ADS representing one ordinary share. The registration statement discloses an indicative pricing range for the proposed offering of U.S.$15.00 – U.S.$17.00 per ADS. This would represent an increase in value of Syncona’s current shareholding in Autolus (compared to the 30 April 2018 sterling holding value) of £49.5 – £67.7 million[1] (7.4p-10.2p per Syncona share). The proposed maximum aggregate offering amount specified in the filing is U.S.$125.0 million, which assumes that the offering price is at the midpoint of the indicative pricing range and does not include the underwriters’ option to purchase additional ADSs.
alan@bj
31/5/2018
17:47
Indeed it is moving along nicely. I like the business models which allows exposure to a portfolio of life science start-ups which would otherwise be unavailable for investment. Definitely less risky than buying in to early stage companies reliant on a single technology.
audigger
25/5/2018
15:54
.....and today another high.Where is everybody?
ltinvestor
24/5/2018
09:22
Today the share price has reached an all time high and no wonder with its holdings.Under the radar at the moment with Pi’s but not institutions.
ltinvestor
15/5/2018
14:20
hxxps://www.businesswire.com/news/home/20180514005319/en/Blue-Earth-Diagnostics-Announces-Presentation-Fluciclovine-18F Apparently a poster on the results of the LOCATE clinical trial (NCT02680041) will be presented in the next week. 220 patients for: Primary Outcome Measures : The fraction of patients for whom 18F-fluciclovine PET/CT alters patient planned treatment through detection of disease. [ Time Frame: 2-22 days post PET CT ] The change of management will be based on referring physician questionnaires completed pre- and post- 18F-fluciclovine PET/CT Secondary Outcome Measures : The fraction of patients for whom 18F-fluciclovine PET/CT alters patient actual treatment [ Time Frame: 6 months ] The rate of detection of any disease site by 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ] The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT The rate of detection of 1) local and pelvic disease and 2) distant metastases with 18F-fluciclovine PET/CT in the study population [ Time Frame: 1 week ] The percentage of subjects who have disease detectable by 18F-fluciclovine PET/CT 1) in the pelvis and 2) distally
luxaeterna1
15/5/2018
11:56
I was very fortunate and bought in during the first few weeks of the fund @ about £1.30. Thankfully it was a modest purchase, offsetting some fairly terrible other stocks in my portfolio!
luxaeterna1
13/5/2018
10:48
I bought a large number at £1.65 so very happy.
ltinvestor
13/5/2018
09:42
I am invested here. I bought in at 159p.
alan@bj
13/5/2018
08:14
Alan.Autolus have built a “switch” in the Car T cell so they have the ability to can turn off the treatment at any time.Syncona is under the PI radar at the moment but not the institutions.This is one investment that you lock in the bottom drawer and watch it grow year on year.Dyor and do not take this as investment advice...
ltinvestor
12/5/2018
14:37
Thank you Iti.
alan@bj
12/5/2018
13:19
It is on one of the forms and apparently is an approximation.If you google Autolus you will find a couple of articles re the listing etc
ltinvestor
11/5/2018
17:24
Where did you find that information, Iti? Is Syncona participating in the fund raising?
alan@bj
11/5/2018
16:42
Raising $100m prior to listing..
ltinvestor
10/5/2018
20:26
Therein lies opportunity :-) DL
davidlloyd
08/5/2018
08:20
No price movement on announcement as no details.
brexitplus
08/5/2018
07:42
Syncona have a 38.6% share of Autolus and the Nasdaq listing should show a significant uplift in Synconas nav.
ltinvestor
08/5/2018
07:12
Autolus files for proposed initial public offering in the United States 8 May 2018 Syncona Ltd, a leading healthcare company focused on investing in and building global leaders in life science, today notes that its portfolio company Autolus Therapeutics Limited (to be reorganised as Autolus Therapeutics plc) (“Autolus̶1;) has filed a registration statement on Form F-1 (“Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share. All ADSs to be sold in the proposed IPO will be offered by Autolus. Autolus intends to apply to list its ADSs on the Nasdaq Global Market under the ticker symbol “AUTL”. The number of ADSs to be sold and the pricing terms for the proposed IPO have not yet been determined.
brexitplus
Chat Pages: 734  733  732  731  730  729  728  727  726  725  724  723  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180620 16:54:33